|
An open label, randomized phase III trial evaluating the treatment (tx) effects of panitumumab (pmab) + best supportive care (BSC) versus BSC in chemorefractory wild-type (WT) KRAS exon 2 metastatic colorectal cancer (mCRC) and in WT RAS mCRC. |
|
|
|
Research Funding - Bayer (Inst); Merck Serono (Inst); Roche (Inst) |
|
|
Consulting or Advisory Role - Merck; Roche |
Research Funding - Amgen; MOLOGEN; Taiho Pharmaceutical |
Travel, Accommodations, Expenses - Amgen; Bayer; Roche |
|
|
No Relationships to Disclose |
|
|
Research Funding - AstraZeneca; Celgene; GlaxoSmithKline; Sanofi |
|
|
Honoraria - Amgen; AstraZeneca; Bristol-Myers Squibb; Bristol-Myers Squibb; Sandoz; Sanofi |
Consulting or Advisory Role - Acraf; Amgen; Bristol-Myers Squibb; Teva |
Travel, Accommodations, Expenses - Astellas Pharma; Roche; Teva |
|
|
Honoraria - II Dong Pharmaceuticals; Roche |
Consulting or Advisory Role - Bayer |
|
|
No Relationships to Disclose |
|
Ricardo Villalobos Valencia |
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
|
Stock and Other Ownership Interests - Amgen |
|
|
No Relationships to Disclose |
|
|
|
Stock and Other Ownership Interests - Amgen |
|
|
|
Stock and Other Ownership Interests - Amgen |
|
|
Honoraria - AstraZeneca; Pfizer; Roche |
Consulting or Advisory Role - Amgen; Astellas Pharma; AstraZeneca; Pfizer; Roche |
|
Travel, Accommodations, Expenses - Pfizer; Roche |